Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association of Plasma Neurofilament Light Chain With Diagnostic Classification in a Neuromuscular Referral Cohort: A Cross-Sectional Study.

Neurology·2026
Same author

Isolated Peripheral Nervous System Presentation in Ma/Ma2-Associated Autoimmunity.

Neurology(R) neuroimmunology & neuroinflammation·2026
Same author

Gephyrin Neurological Autoimmunity.

Annals of neurology·2026
Same author

Septin multimer autoantibodies in severe motor neuropathy mimicking lower motor neuron disease.

Brain : a journal of neurology·2026
Same author

AEGIS reveals epitope- and clone-resolved convergence of CNS B and T cell autoreactivity in ROHHAD.

bioRxiv : the preprint server for biology·2026
Same author

Long-Term Outcomes in Stiff Person Spectrum Disorder.

European journal of neurology·2026

Related Experiment Video

Updated: Jan 6, 2026

Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis
26:48

Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis

Published on: July 4, 2007

18.7K

Development of anti-LGI1 autoimmune encephalitis outcome rating score using the Rasch analysis.

Xiaoyang Li1,2,3, Pranjal Gupta1,2, Naveen K Paramasivan1,2

  • 1Department of Neurology, Mayo Clinic, Rochester, MN, USA.

Journal of Neurology
|November 11, 2025
PubMed
Summary

A new LOR score effectively measures anti-LGI1 autoimmune encephalitis severity. This reliable and responsive outcome measure aids clinical trials and practice for this immunotherapy-responsive condition.

Keywords:
Anti-LGI1 autoimmune encephalitisAutoimmune epilepsyOutcome measuresOutcome rating scaleRasch analysis

More Related Videos

Author Spotlight: Unveiling the Pathway Linking Obesity to Autoimmune Inflammation in Multiple Sclerosis
08:17

Author Spotlight: Unveiling the Pathway Linking Obesity to Autoimmune Inflammation in Multiple Sclerosis

Published on: February 23, 2024

5.5K
Sagittal Plane Kinematic Gait Analysis in C57BL/6 Mice Subjected to MOG35-55 Induced Experimental Autoimmune Encephalomyelitis
13:02

Sagittal Plane Kinematic Gait Analysis in C57BL/6 Mice Subjected to MOG35-55 Induced Experimental Autoimmune Encephalomyelitis

Published on: November 4, 2017

9.1K

Related Experiment Videos

Last Updated: Jan 6, 2026

Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis
26:48

Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis

Published on: July 4, 2007

18.7K
Author Spotlight: Unveiling the Pathway Linking Obesity to Autoimmune Inflammation in Multiple Sclerosis
08:17

Author Spotlight: Unveiling the Pathway Linking Obesity to Autoimmune Inflammation in Multiple Sclerosis

Published on: February 23, 2024

5.5K
Sagittal Plane Kinematic Gait Analysis in C57BL/6 Mice Subjected to MOG35-55 Induced Experimental Autoimmune Encephalomyelitis
13:02

Sagittal Plane Kinematic Gait Analysis in C57BL/6 Mice Subjected to MOG35-55 Induced Experimental Autoimmune Encephalomyelitis

Published on: November 4, 2017

9.1K

Area of Science:

  • Neurology
  • Immunology
  • Clinical Outcomes Research

Background:

  • Anti-LGI1 autoimmune encephalitis is a treatable neurological disorder with increasing research interest.
  • Developing reliable outcome measures is crucial for advancing clinical trials in this field.
  • Current limitations in outcome assessment hinder progress in anti-LGI1 autoimmune encephalitis research.

Purpose of the Study:

  • To design and validate a disease-specific outcome measure for anti-LGI1 autoimmune encephalitis.
  • To develop a reliable and sensitive tool for assessing patient status in clinical settings and trials.

Main Methods:

  • Expert consensus and literature review informed the initial design of the anti-LGI1 autoimmune encephalitis outcome rating (LOR) score.
  • Rasch analysis was employed to evaluate and refine the psychometric properties of the LOR score using development and validation cohorts.
  • The score's responsiveness was assessed in a longitudinal cohort to determine its ability to detect clinical changes.

Main Results:

  • The finalized LOR score comprises 6 items assessing seizures, cognition, behavior, and gait, with strong psychometric properties.
  • The LOR score demonstrated superior performance over the CASE score in capturing patient severity without significant floor or ceiling effects.
  • Excellent inter-rater and intra-rater reliability (κ > 0.85) and good reliability (0.63) were observed, indicating minimal random error.

Conclusions:

  • The LOR score is a psychometrically sound, reliable, sensitive, and responsive outcome measure for anti-LGI1 autoimmune encephalitis.
  • This validated score can be utilized in both clinical practice and clinical trial settings.
  • The LOR score facilitates better assessment and monitoring of patients with anti-LGI1 autoimmune encephalitis.